P/E ratio for Inovio Pharmaceuticals (INO)

P/E ratio history for Inovio Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Pfizer PFE	15.9	-254.93%	🇺🇸 USA
Johnson & Johnson JNJ	11.7	-213.69%	🇺🇸 USA
Arrowhead Pharmaceuticals ARWR	-12.4	20.82%	🇺🇸 USA
Novartis NVS	31.0	-401.30%	🇨🇭 Switzerland
Merck MRK	64.4	-725.25%	🇺🇸 USA
GlaxoSmithKline GSK	11.9	-215.51%	🇬🇧 UK
Gilead Sciences GILD	19.1	-285.69%	🇺🇸 USA
Cleveland BioLabs CBLI	N/A	N/A	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.